Nature

Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in TN CLL in the 6-year Follow-up of ELEVATE-TN

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
ascopubs.org

Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up.

Pattern of rasburicase (RAS) use in community oncology programs and impact on tumor lysis syndrome (TLS) outcomes. TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after ...
ascopubs.org

Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive (TN) chronic lymphocytic leukemia (CLL): A matching ...

Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: A real-world study. This is an ASCO Meeting Abstract ...
Pharmabiz

AstraZeneca announces phase III ELEVATE TN trial of Calquence significantly prolonged time patients lived without disease progression or death in previously untreated CLL

AstraZeneca presented results from the interim analysis of the phase III ELEVATE TN trial, showing that Calquence (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved ...